Neorecormon epobeta

Manufactured by Roche

Sourced in Germany, United Kingdom

NeoRecormon (EPObeta) is a recombinant human erythropoietin (EPO) product manufactured by Roche. It is an injectable medication used to treat anemia by stimulating the production of red blood cells.

Automatically generated - may contain errors

Lab products found in correlation

Endoproteinase glu c, by Merck Group (1 mentions)

2 protocols using neorecormon epobeta

EPO Beta Sample Preparation Protocol

Check if the same lab product or an alternative is used in the 5 most similar protocols

EPO samples
used in this study were prepared from NeoRecormon (EPO
beta) drug substance material from Roche Diagnostics GmbH (Penzberg,
Germany). Endoproteinase GluC, guanidinium hydrochloride (Gua-HCl),
tris(hydroxymethyl)aminomethane (Tris), 1,4-dithiothreitol (DTT),
and NAP-5 gel filtration columns were from Sigma-Aldrich/Merck KGaA
(Darmstadt, Germany). Ammonium hydrogen carbonate, acetonitrile (ACN),
formic acid (FA), and iodoacetic acid (IAA) were obtained from Fisher
Scientific International Inc. (Pittsburgh, PA, USA).

Čaval T., Buettner A., Haberger M., Reusch D, & Heck A.J. (2021). Discrepancies between High-Resolution Native and Glycopeptide-Centric Mass Spectrometric Approaches: A Case Study into the Glycosylation of Erythropoietin Variants. Journal of the American Society for Mass Spectrometry, 32(8), 2099-2104.

+ Open protocol

+ Expand

Endurance-Trained Males' Erythropoietin Response

Check if the same lab product or an alternative is used in the 5 most similar protocols

Sample characteristics and experimental design have previously been described in detail in Durussel et. Al 20 . Briefly, 18 endurance-trained males (mean ± SD, age: 26.5 ± 5.0 yr, body mass: 74.8 ± 7.7 kg, height: 179.5 ± 5.4 cm; VO2max: runners 60.3 ± 5 ml•kg•min -1 and other activities 51.6 ± 3.5 ml•kg•min -1 ) not involved in sporting competition during the study period were recruited in Glasgow, Scotland. All subjects received 50 IU.kg -1 body mass subcutaneous injections of rHuEpo (Neorecormon-Epo beta, Hoffmann-La Roche Ltd, UK) every 2 days over 4 weeks. Plasma, serum and urine were sampled twice at baseline, i.e. two weeks before the intervention (B1 and B2; days -14, -7, respectively), during (EPO 3-5; days 2, 14 and 28 from rHuEpo administration) and post (Post 6-8; weeks 7-10) rHuEpo administration with an overview of the study design provided in Figure 1.A.

Lima G., Shurlock J., Wang G., Karanikolou A., Sutehall S., Pitsiladis Y.P, & D'Alessandro A. (2023). Metabolomic Profiling of Recombinant Erythropoietin (rHuEpo) in Trained Caucasian Athletes. Clinical journal of sport medicine : official journal of the Canadian Academy of Sport Medicine, 33(5).

+ Open protocol

+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Revolutionizing how scientists
search and build protocols!